PURPOSE: Heart failure (HF) is a primary cause of morbidity and mortality worldwide, with significant impact on life quality and extensive healthcare costs. Assessment of myocardial sympathetic innervation function plays a central role in prognosis assessment in HF patients. The aim of this review is to summarize the most recent evidence regarding the clinical applications of iodine-123 metaiodobenzylguanidine (123I-MIBG) imaging in patients with HF and related comorbidities. METHODS: A comprehensive literature search was conducted on PubMed and Web of Science databases. Articles describing the impact of 123I-MIBG imaging on HF and related comorbidities were considered eligible for the review. RESULTS: We collected several data reporting that 123I-MIBG imaging is a safe and non-invasive tool to evaluate dysfunction of cardiac sympathetic neuronal function and to assess risk stratification in HF patients. HF is frequently associated with comorbidities that may affect cardiac adrenergic innervation. Furthermore, HF is frequently associated with comorbidities and chronic conditions, such as diabetes, obesity, kidney disease and others, that may affect cardiac adrenergic innervation. CONCLUSION: Comorbidities and chronic conditions lead to more severe impairment of sympathetic nervous system in patients with HF, with a negative impact on disease progression and outcome. Cardiac imaging with 123I-MIBG can be a useful tool to reduce morbidity and prevent adverse events in HF patients.
PURPOSE: Heart failure (HF) is a primary cause of morbidity and mortality worldwide, with significant impact on life quality and extensive healthcare costs. Assessment of myocardial sympathetic innervation function plays a central role in prognosis assessment in HF patients. The aim of this review is to summarize the most recent evidence regarding the clinical applications of iodine-123 metaiodobenzylguanidine (123I-MIBG) imaging in patients with HF and related comorbidities. METHODS: A comprehensive literature search was conducted on PubMed and Web of Science databases. Articles describing the impact of 123I-MIBG imaging on HF and related comorbidities were considered eligible for the review. RESULTS: We collected several data reporting that 123I-MIBG imaging is a safe and non-invasive tool to evaluate dysfunction of cardiac sympathetic neuronal function and to assess risk stratification in HF patients. HF is frequently associated with comorbidities that may affect cardiac adrenergic innervation. Furthermore, HF is frequently associated with comorbidities and chronic conditions, such as diabetes, obesity, kidney disease and others, that may affect cardiac adrenergic innervation. CONCLUSION: Comorbidities and chronic conditions lead to more severe impairment of sympathetic nervous system in patients with HF, with a negative impact on disease progression and outcome. Cardiac imaging with 123I-MIBG can be a useful tool to reduce morbidity and prevent adverse events in HF patients.
Authors: Geoffrey M Currie; Basit Iqbal; Janelle M Wheat; Lexin Wang; Marko Trifunovic; Herbert F Jelinek; Hosen Kiat Journal: J Nucl Med Technol Date: 2011-10-03
Authors: Arnold F Jacobson; Roxy Senior; Manuel D Cerqueira; Nathan D Wong; Gregory S Thomas; Victor A Lopez; Denis Agostini; Fred Weiland; Harish Chandna; Jagat Narula Journal: J Am Coll Cardiol Date: 2010-02-25 Impact factor: 24.094
Authors: Theresa A McDonagh; Marco Metra; Marianna Adamo; Roy S Gardner; Andreas Baumbach; Michael Böhm; Haran Burri; Javed Butler; Jelena Čelutkienė; Ovidiu Chioncel; John G F Cleland; Andrew J S Coats; Maria G Crespo-Leiro; Dimitrios Farmakis; Martine Gilard; Stephane Heymans; Arno W Hoes; Tiny Jaarsma; Ewa A Jankowska; Mitja Lainscak; Carolyn S P Lam; Alexander R Lyon; John J V McMurray; Alexandre Mebazaa; Richard Mindham; Claudio Muneretto; Massimo Francesco Piepoli; Susanna Price; Giuseppe M C Rosano; Frank Ruschitzka; Anne Kathrine Skibelund Journal: Eur Heart J Date: 2021-09-21 Impact factor: 29.983
Authors: Mariano Pontico; Gabriele Brunotti; Miriam Conte; Ferdinando Corica; Laura Cosma; Cristina De Angelis; Maria Silvia De Feo; Julia Lazri; Antonio Matto; Melissa Montebello; Arianna Di Rocco; Viviana Frantellizzi; Alessio Farcomeni; Giuseppe De Vincentis Journal: J Nucl Cardiol Date: 2021-01-13 Impact factor: 3.872